Publication | Open Access
Omadacycline for Community-Acquired Bacterial Pneumonia
215
Citations
17
References
2019
Year
Omadacycline was noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults. (Funded by Paratek Pharmaceuticals; OPTIC ClinicalTrials.gov number, NCT02531438 .).
| Year | Citations | |
|---|---|---|
Page 1
Page 1